Statins and neuroprotection: basic pharmacology needed (Q38182926)

30 August 2017

Statins and neuroprotection: basic pharmacology needed (English)

1 reference

30 August 2017

1 reference

W Gibson Wood

1

1 reference

30 August 2017

Walter E Mΰller

series ordinal

2

1 reference

30 August 2017

Gunter P Eckert

series ordinal

3

1 reference

30 August 2017

29 January 2014

1 reference

30 August 2017

Molecular Neurobiology

1 reference

30 August 2017

50

1 reference

30 August 2017

1

1 reference

30 August 2017

214-220

1 reference

https://scigraph.springernature.com/pub.10.1007/s12035-014-8647-3

30 August 2017

0 references

cites work

The role of statins in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Diverse effects of statins on angiogenesis: new therapeutic avenues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Update on statins: hope for osteoporotic fracture healing treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Statins: mechanisms of neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Statins: multiple neuroprotective mechanisms in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Statins in the treatment of acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Evidence for the efficacy of statins in animal stroke models: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Cholesterol and statins in Alzheimer's disease: current controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Alzheimer's disease, cholesterol, and statins: the junctions of important metabolic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Statins for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Statin use and risk of Parkinson's disease: a meta-analysis of observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Why aging research? The moral imperative to retard human aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Mammalian carboxylesterase 3: comparative genomics and proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Statins, Bcl-2, and apoptosis: cell death or cell protection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Monocarboxylate transporter mediates uptake of lovastatin acid in rat cultured mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

The role of monocarboxylate transporter 2 and 4 in the transport of gamma-hydroxybutyric acid in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

The monocarboxylate transporter family--role and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Inhibitory effects of statins on human monocarboxylate transporter 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Predominantly neuronal expression of cytochrome P450 isoforms CYP3A11 and CYP3A13 in mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Mouse cytochrome P450 (Cyp3a11): predominant expression in liver and capacity to activate aflatoxin B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Concordant up-regulation of cytochrome P450 Cyp3a11, testosterone oxidation and androgen receptor expression in mouse brain after xenobiotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

The P-glycoprotein multidrug transporter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

HMG-CoA reductase inhibitors and P-glycoprotein modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Drug efflux transporters in the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Isoprenoids and Alzheimer's disease: a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Isoprenoids, small GTPases and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Isoprenoid quantitation in human brain tissue: a validated HPLC-fluorescence detection method for endogenous farnesyl- (FPP) and geranylgeranylpyrophosphate (GGPP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Therapeutic intervention based on protein prenylation and associated modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Distribution, metabolism and function of dolichol and polyprenols

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Coenzyme Q10 and cognition in atorvastatin treated dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Increased nonsterol isoprenoids, dolichol and ubiquinone, in the Smith-Lemli-Opitz syndrome: effects of dietary cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-014-8647-3

Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations

21 January 2018

1 reference

12 December 2020

Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat

1 reference

12 December 2020

Statins and neuroprotection: a prescription to move the field forward

1 reference

12 December 2020

Expression, activity and regulation of CYP3A in human and rodent brain

1 reference

12 December 2020

High levels of brain dolichols in neuronal ceroid-lipofuscinosis and senescence

1 reference

12 December 2020

Membrane properties of dolichol in different age groups of mice

1 reference

12 December 2020

Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. 4

1 reference

12 December 2020

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

12 December 2020

Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications

1 reference

12 December 2020

Monocarboxylate transporters in the central nervous system: distribution, regulation and function.

1 reference

12 December 2020

Effects of inhibitors of hydroxymethylglutaryl coenzyme A reductase on coenzyme Q and dolichol biosynthesis.

1 reference

12 December 2020

Preclinical and clinical pharmacology of cerivastatin

1 reference

12 December 2020

Dolichols are elevated in brain tissue from Alzheimer's disease, but not in urinary sediment from Alzheimer's disease and Down's syndrome.

1 reference

12 December 2020

A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro

1 reference

12 December 2020

In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase

1 reference

12 December 2020

10.1007/S12035-014-8647-3

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

0 references

1 reference